Gehin, Johanna E. http://orcid.org/0000-0002-9896-0223
Klaasen, Rolf A. http://orcid.org/0000-0002-6078-5108
Norli, Ellen S. http://orcid.org/0000-0001-7777-0714
Warren, David J. http://orcid.org/0000-0001-6854-1282
Syversen, Silje W. http://orcid.org/0000-0003-2159-3696
Goll, Guro L. http://orcid.org/0000-0002-8506-725X
Bjøro, Trine http://orcid.org/0000-0001-5578-615X
Kvien, Tore K. http://orcid.org/0000-0002-8441-3093
Mjaavatten, Maria D. http://orcid.org/0000-0003-0692-3271
Bolstad, Nils
Funding for this research was provided by:
University of Oslo
Article History
Received: 15 March 2021
Accepted: 12 April 2021
First Online: 4 May 2021
Declarations
:
: SWS Thermo Fisher. GLG Abbvie, Biogen, Boehringer Ingelheim, Orion Pharma, Eli Lilly, Novartis, Pfizer, MSD, Roche, UCB. TKK AbbVie, Amgen, Biogen, BMS, Celltrion, Egis, Eli Lilly, Ewapharma, Ewopahrma, Gilead, Hikma, MSD, Mylan, Novartis, Oktal, Pfizer, Roche, Sandoz, Sanofi, UCB. NB Takeda, Roche, Janssen, Novartis, The remaining authors: None declared. Disclosures listed above include fees for speaking and/or consulting or research funding to the institution (Diakonhjemmet Hospital).
: The study was approved by the Regional Ethics Committee of Eastern Norway.
: All patients provided written, informed consent before inclusion.
: Not applicable.